AR122013A1 - Composiciones de virus adenoasociados compatibles entre especies y métodos para su uso - Google Patents

Composiciones de virus adenoasociados compatibles entre especies y métodos para su uso

Info

Publication number
AR122013A1
AR122013A1 ARP210101222A ARP210101222A AR122013A1 AR 122013 A1 AR122013 A1 AR 122013A1 AR P210101222 A ARP210101222 A AR P210101222A AR P210101222 A ARP210101222 A AR P210101222A AR 122013 A1 AR122013 A1 AR 122013A1
Authority
AR
Argentina
Prior art keywords
methods
adeno
associated virus
species
compatible
Prior art date
Application number
ARP210101222A
Other languages
English (en)
Inventor
Aravind Asokan
Trevor Gonzalez
Lawrence Patrick Havlik
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of AR122013A1 publication Critical patent/AR122013A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

Vectores de virus adenoasociados (AAV) que comprenden variantes de proteínas de la cápside, composiciones farmacéuticas, métodos para su elaboración y métodos para su administración a un sujeto.
ARP210101222A 2020-05-05 2021-05-05 Composiciones de virus adenoasociados compatibles entre especies y métodos para su uso AR122013A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063020062P 2020-05-05 2020-05-05

Publications (1)

Publication Number Publication Date
AR122013A1 true AR122013A1 (es) 2022-08-03

Family

ID=78468375

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101222A AR122013A1 (es) 2020-05-05 2021-05-05 Composiciones de virus adenoasociados compatibles entre especies y métodos para su uso

Country Status (13)

Country Link
US (3) US20230151389A1 (es)
EP (1) EP4125977A2 (es)
JP (1) JP2023524291A (es)
KR (1) KR20230029616A (es)
CN (1) CN116096377A (es)
AR (1) AR122013A1 (es)
AU (1) AU2021268946A1 (es)
BR (1) BR112022022644A2 (es)
CA (1) CA3177869A1 (es)
IL (1) IL297577A (es)
MX (1) MX2022013963A (es)
TW (1) TW202208631A (es)
WO (1) WO2021226267A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024044725A2 (en) * 2022-08-24 2024-02-29 Regenxbio Inc. Recombinant adeno-associated viruses and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2648241T3 (es) * 2003-09-30 2017-12-29 The Trustees Of The University Of Pennsylvania Clados de virus adenoasociados (AAV), secuencias, vectores que contienen el mismo, y usos de los mismos
US10746742B2 (en) * 2014-04-25 2020-08-18 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping

Also Published As

Publication number Publication date
CA3177869A1 (en) 2021-11-11
JP2023524291A (ja) 2023-06-09
CN116096377A (zh) 2023-05-09
AU2021268946A1 (en) 2022-12-01
US20230151389A1 (en) 2023-05-18
TW202208631A (zh) 2022-03-01
KR20230029616A (ko) 2023-03-03
BR112022022644A2 (pt) 2023-01-17
WO2021226267A2 (en) 2021-11-11
EP4125977A2 (en) 2023-02-08
US20240067988A1 (en) 2024-02-29
WO2021226267A3 (en) 2021-12-16
US20240076695A1 (en) 2024-03-07
MX2022013963A (es) 2023-02-22
IL297577A (en) 2022-12-01

Similar Documents

Publication Publication Date Title
CO2022016156A2 (es) Redirección del tropismo de las cápsides de aav
CL2023000264A1 (es) Nuevos vectores virales adeno-asociados dirigidos al hígado
CL2020003176A1 (es) Novedosas proteínas de la cápside del virus adenoasociado (divisional sol. 201900167).
AR118465A1 (es) Vectores de virus adenoasociados recombinantes
BR112018011711A2 (pt) peptídeos de direcionamento para direcionar virus adeno-associados (aav)
CL2018000587A1 (es) Adenovirus oncolítico que codifica una proteína b7 (divisional de sol. n° 2731-2017)
BR112018006074A2 (pt) vetores de fator viii de vírus adeno-associado, partículas virais associadas e formulações terapêuticas compreendendo as mesmas
BR112018008766A2 (pt) variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos
CL2021002586A1 (es) Anticuerpos de cadena pesada que se unen al psma
ECSP034439A (es) Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c
CL2023001793A1 (es) Anticuerpos anti-componente de complemento y métodos de uso
AR029851A1 (es) Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
BR112021020957A2 (pt) Capsídeos de vírus adenoassociado (aav) variante para liberação intravítrea
CL2020002797A1 (es) Composiciones sólidas que comprenden un agonista de glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
BR112021012667A2 (pt) Proteínas de ligação anti-pd-1 e métodos de uso destas
BR112018072264A2 (pt) composição farmacêutica
EA202190318A1 (ru) Составы вакцин, содержащие систему консервантов
CO2020016147A2 (es) Composiciones de virus adenoasociado (aav)
AR122013A1 (es) Composiciones de virus adenoasociados compatibles entre especies y métodos para su uso
EA201391200A1 (ru) Способы и композиции для вакцинации от staphylococcus aureus
CO2021010786A2 (es) Toxinas apxia, apxiia y apxiiia inactivadas
UY39715A (es) Anticuerpos anti-il-2r agonistas y métodos de uso
CL2023000491A1 (es) Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).
CO2021014748A2 (es) Conjugado de anticuerpo anti-bcma, composiciones que lo comprenden, y métodos de fabricación y uso del mismo
CL2023001140A1 (es) Formulaciones de anticuerpos anti-pd-l1